Pavmed Sustainability Profile
Pavmed Inc., a pioneering medical technology company headquartered in the United States, was founded in 2014. The company focuses on developing innovative solutions across various medical fields, including gastroenterology, urology, and general surgery. With a commitment to enhancing patient care, Pavmed has introduced unique products such as the EsoGuard® and the CarpX® device, which stand out for their advanced design and efficacy. Operating primarily in the US, Pavmed has achieved significant milestones, including successful clinical trials and regulatory approvals that underscore its market position. The company is dedicated to addressing unmet medical needs, making it a notable player in the medical device industry. With a strong emphasis on innovation and patient outcomes, Pavmed continues to shape the future of healthcare technology.
DitchCarbon Score
How does Pavmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pavmed's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pavmed's reported carbon emissions
In 2023, Pavmed Inc., headquartered in the US, reported total carbon emissions of approximately 115,790 kg CO2e, comprising 65,440 kg CO2e from Scope 1 and 50,350 kg CO2e from Scope 2 emissions. This marks a notable increase from 2022, when the company emitted about 97,620 kg CO2e (61,200 kg CO2e from Scope 1 and 36,420 kg CO2e from Scope 2). Pavmed has committed to achieving net zero carbon emissions by 31 December 2030, as part of a comprehensive decarbonisation strategy. This long-term target encompasses all scopes of emissions, reflecting the company's dedication to mitigating its environmental impact. The commitment is designed to align with industry standards for climate action and demonstrates a proactive approach to sustainability. Pavmed's emissions data is not cascaded from any parent organisation, indicating that the figures are independently reported. The company continues to focus on reducing its carbon footprint while enhancing its operational efficiency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 20,998,000 | 00,000,000 | 00,000,000 | 00,000 | 000,000,000 |
| Scope 2 | 17,151,000 | 00,000,000 | 00,000,000 | 00,000 | 000,000,000 |
| Scope 3 | - | - | - | 0,000,000 | 000,000 |
How Carbon Intensive is Pavmed's Industry?
How Carbon Intensive is Pavmed's Location?
Pavmed's Scope 3 Categories Breakdown
Pavmed's Scope 3 emissions, which decreased by 90% last year and decreased by approximately 90% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Waste Generated in Operations" being the largest emissions source at 73% of Scope 3 emissions.
Top Scope 3 Categories
Pavmed's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pavmed has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
